CDKN1C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 217 bp deletion in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 217 bp deletion in exon 1
Alternative names
BWCR, BWS, Beckwith Wiedemann syndrome, CDKI, CDKN 1C, CDN1C_HUMAN, Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, KIP 2, WBS, p57, p57 Kip 2
What's included?
Recommended products
CDKN1C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 217 bp deletion in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 217 bp deletion in exon 1
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- CDKN1C
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The protein p57^Kip2 also known as CDKN1C plays an important role as a cyclin-dependent kinase inhibitor aligning closely with proteins like p21 and p27. It weighs approximately 57 kiloDaltons. P57^Kip2's expression occurs in various tissues including the placenta muscle brain and kidney. This widespread expression suggests a multitiered function in different tissues. Researchers use p57 immunostain techniques to confirm its presence in tissues.
- Biological function summary
P57^Kip2 acts as a regulator of cell cycle progression. It binds directly to cyclin-CDK complexes stopping cell cycle transition from G1 to S phase. This action prevents unregulated cell division and contributes to cellular differentiation. p57^Kip2 forms part of larger protein complexes further influencing various cellular processes. Its activity is important for embryonic development where it controls cell proliferation rates.
- Pathways
P57^Kip2 integrates into pathways controlling cell cycle checkpoints and apoptosis. It interacts with proteins like cyclin D and E and the retinoblastoma protein (Rb) within the cell cycle regulation pathway. Additionally its presence in growth signaling pathways intersects with TGF-beta signaling. These pathways hold significant influence over development and cellular responses to DNA damage.
- Associated diseases and disorders
Abnormal expression of p57^Kip2 connects with cancers and growth disorders. Loss of function or downregulation often links to overgrowth syndromes like Beckwith-Wiedemann syndrome. Conversely reduced expression levels associate with cancer proliferation particularly in cases such as Wilms' tumor. This association intertwines with mutations in genes like IGF2 and H19 which are critical in these conditions.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human CDKN1C (p57 Kip2) knockout HeLa cell lysate (ab280120)
Lane 1: Wild-type HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277359 cell lysate 20 μg
Lane 2: Wild-type HeLa Treated Dexamethasone (50 nM, 16 h) ab287335 cell lysate 20 μg
Lane 3: CDKN1C knockout HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277299 cell lysate 20 μg
Lane 4: CDKN1C knockout HeLa Treated Dexamethasone (50 nM, 16 h) ab281877 cell lysate 20 μg
Lane 5: MCF7 cell lysate 20 μg
Lane 6: SH-SY5Y cell lysate 20 μg
False colour image of Western blot: Anti-p57 Kip2 antibody [EP2516] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-p57 Kip2 antibody [EP2516] ab119989 was shown to bind specifically to p57 Kip2. A band was observed at 50 kDa in wild-type HeLa cell lysates with no signal observed at this size in CDKN1C knockout cell line Human CDKN1C (p57 Kip2) knockout HeLa cell line ab280061 (knockout cell lysate ab280120). To generate this image, wild-type and CDKN1C knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) at 1/20000 dilution.All lanes: Western blot - Anti-p57 Kip2 antibody [EP2516] (Anti-p57 Kip2 antibody [EP2516] ab119989) at 1/1000 dilution
Lane 1: Wild-type HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277359 cell lysate at 20 µg
Lane 2: Wild-type HeLa Treated Dexamethasone (50 nM, 16 h) ab287335 cell lysate at 20 µg
Lane 2: Western blot - Human CDKN1C (p57 Kip2) knockout HeLa cell line (Human CDKN1C (p57 Kip2) knockout HeLa cell line ab280061)
Lane 3: CDKN1C knockout HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277299 cell lysate at 20 µg
Lane 4: CDKN1C knockout HeLa Treated Dexamethasone (50 nM, 16 h) ab281877 cell lysate at 20 µg
Lane 5: MCF7 cell lysate at 20 µg
Lane 6: SH-SY5Y cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 32 kDa
Observed band size: 50 kDa
Sanger Sequencing - Human CDKN1C (p57 Kip2) knockout HeLa cell lysate (ab280120)
217 bp Deletion in Exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com